로딩 중…
지수 로딩 중…
큐리언트
115180· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩19,690-7.56%
2026-06-26
Price Chart
큐리언트+66.16%
Financials
Investment Metrics(as of 2026-06-26)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 738.59B KRW |
| Revenue | 7.00B KRW |
| Net Income | -31.97B KRW |
| Total Assets | 54.70B KRW |
| Net Assets | 32.82B KRW |
| Employees | 33 |
| Value | |
| P/B | 22.50x |
| P/S | 105.45x |
| FCF Yield | -3.89% |
| Profitability | |
| ROE | -97.39% |
| ROA | -58.44% |
| Op. Margin | -438.41% |
| Revenue Growth | 1.12% |
| Financial Health | |
| Debt Ratio | 166.65% |
| Total Debt | 9.42B KRW |
| FCF | -28.73B KRW |
| Cash | 9.48B KRW |
| Current Ratio | 19.26x |
| Performance | |
| 1Y Return | 66.16% |
| 1M Return | -37.39% |
| From 52W High | -68.70% |
| 1Y MDD | -61.32% |
| Trading | |
| Volume | 136,278 shares |
| Foreign Own. | 6.05% |
| Per Share | |
| EPS | -871 KRW |
| BPS | 736 KRW |
Company Info
QURIENT was established in 2008 to commercialize research from the Korea Pasteur Institute and listed on KOSDAQ in 2016. Specializing in pharmaceutical research and development, it possesses innovative new drug pipelines including MOCASICLIP, QP101, and AADRIXETINIB. The company prioritizes anti-cancer and autoimmune disease projects through a strategic alliance with the Max Planck Institute and pursues revenue generation by developing combination therapies with MSD's KEYTRUDA. QURIENT is headquartered in Seongnam-si, Gyeonggi-do.